Dr. Levine on Immunotherapy for Endometrial Cancer

Douglas A. Levine, MD
Published: Tuesday, Sep 19, 2017



Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Immunotherapy has capitalized on what was already known regarding endometrial cancer, states Levine.

Some microsatellite instability-high tumors are inherited through a defect in mismatch-repair genes, which is important for genetic screening. There is another link between inherited genetic events that are leading to effective treatments, states Levine.
 


Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Immunotherapy has capitalized on what was already known regarding endometrial cancer, states Levine.

Some microsatellite instability-high tumors are inherited through a defect in mismatch-repair genes, which is important for genetic screening. There is another link between inherited genetic events that are leading to effective treatments, states Levine.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x